111 Shares in Insulet Corporation $PODD Bought by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, HoldingsChannel reports. The firm acquired 111 shares of the medical instruments supplier’s stock, valued at approximately $35,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Insulet by 0.6% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after acquiring an additional 48 shares during the period. Mather Group LLC. increased its stake in Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after buying an additional 48 shares during the last quarter. Brooklyn Investment Group increased its stake in Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after buying an additional 52 shares during the last quarter. Cooper Financial Group increased its stake in Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 58 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in Insulet by 2.1% in the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier’s stock valued at $757,000 after buying an additional 60 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the topic of several recent research reports. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Wells Fargo & Company lifted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Rothschild & Co Redburn lifted their price target on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $347.67.

Insulet Stock Up 0.0%

Insulet stock opened at $314.56 on Tuesday. The firm has a market capitalization of $22.14 billion, a PE ratio of 95.61, a P/E/G ratio of 2.61 and a beta of 1.40. The company’s 50-day moving average is $324.28 and its 200-day moving average is $301.03. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.